FDA extends review of Exelixis' zanzalintinib-Tecentriq combo in mCRC by three months to March 3 after new data submission.
September 11, 2026 12:02 PM EDT
R&DPharmaFDA+
FDA extends review of Exelixis' colorectal cancer drug candidate
Zachary Brennan
California-based drug developer Exelixis submitted new safety and efficacy data on its potential treatment of metastatic colorectal cancer (mCRC) to the FDA. The new data …
Exelixis' zanzalintinib misses OS endpoint in mCRC subgroup without liver mets; FDA decision on all-comers approval due Dec 3.
FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.
Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metastatic colorectal cancer…
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
Exelixis CEO Michael Morrissey faces criticism from researchers including Mark Ratain, who allege zanzalintinib is a
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or…
